Literature DB >> 25521725

Importance of cyclooxygenase-1/prostacyclin in modulating gastric mucosal integrity under stress conditions.

Kikuko Amagase1, Nahoko Izumi, Yuka Takahira, Tomoko Wada, Koji Takeuchi.   

Abstract

BACKGROUND AND AIM: We investigated the roles of cyclooxygenase (COX) isozymes and prostaglandins (PGs) and their receptors in mucosal defense against cold-restraint stress (CRS)-induced gastric lesions.
METHODS: Male C57BL/6 wild-type (WT) mice and those lacking COX-1 or COX-2 as well as those lacking EP1, EP3, or IP receptors were used after 18 h fasting. Animals were restrained in Bollman cages and kept in a cold room at 10°C for 90 min.
RESULTS: CRS induced multiple hemorrhagic lesions in WT mouse stomachs. The severity of these lesions was significantly worsened by pretreatment with the nonselective COX inhibitors (indomethacin, loxoprofen) or selective COX-1 inhibitor (SC-560), while neither of the selective COX-2 inhibitors (rofecoxib and celecoxib) had any effect. These lesions were also aggravated in animals lacking COX-1, but not COX-2. The expression of COX-2 mRNA was not detected in the stomach after CRS, while COX-1 expression was observed under normal and stressed conditions. The gastric ulcerogenic response to CRS was similar between EP1 or EP3 knockout mice and WT mice, but was markedly worsened in animals lacking IP receptors. Pretreating WT mice with iloprost (the PGI2 analog) significantly prevented CRS-induced gastric lesions in the presence of indomethacin. PGE2 also reduced the severity of these lesions, and the effect was mimicked by the EP4 agonist, AE1-329.
CONCLUSIONS: These results suggest that endogenous PGs derived from COX-1 play a crucial role in gastric mucosal defense during CRS, and this action is mainly mediated by PGI2 /IP receptors and partly by PGE2 /EP4 receptors.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  EP and IP receptors; cold-restraint stress; cyclooxygenase isozyme; gastric ulcer; mouse; prostaglandins

Mesh:

Substances:

Year:  2014        PMID: 25521725     DOI: 10.1111/jgh.12767

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

2.  Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin.

Authors:  Yu Lai; Wa Zhong; Tao Yu; Zhong-Sheng Xia; Jie-Yao Li; Hui Ouyang; Ti-Dong Shan; Hong-Sheng Yang; Qi-Kui Chen
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

3.  The Use of Pistacia Lentiscus Chia Resin Versus Omeprazole in Protecting Male Rats Peptic Mucosa Against Cold Restraint Stress.

Authors:  Despoina Kakagia; Apostolos Papalois; Maria Lambropoulou; Fotini Papachristou; Gregory Trypsiannis; Constantinos Anagnostopoulos; Mike Pitiakoudis; Alexandra Tsaroucha
Journal:  J Crit Care Med (Targu Mures)       Date:  2020-05-06

4.  Seasonal dynamics and starvation impact on the gut microbiome of urochordate ascidian Halocynthia roretzi.

Authors:  Jiankai Wei; Hongwei Gao; Yang Yang; Haiming Liu; Haiyan Yu; Zigui Chen; Bo Dong
Journal:  Anim Microbiome       Date:  2020-08-18

5.  Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells.

Authors:  Soraya Wilke Saliba; Hannah Jauch; Brahim Gargouri; Albrecht Keil; Thomas Hurrle; Nicole Volz; Florian Mohr; Mario van der Stelt; Stefan Bräse; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2018-11-19       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.